Fractyl outlines plan to cut quarterly operating cash spending to ~$8M by end of Q2 2027 as Revita heads toward de novo submission

• CEO Harith Rajagopalan framed Revita around GLP-1 discontinuation dynamics and said, "Approximately 1 million are discontinuing GLP-1s each month." He positioned Revita as a one-time outpatient approach: "Revita aims to do both. It is

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.